Kristie L. Kahl


Adagrasib Associated With Promising Disease Control Rate in KRAS G12C–Mutant NSCLC

June 09, 2022

Investigators reported an objective response rate of 43% and a disease control rate of 80% among patients with previously treated KRAS G12C–mutated non–small cell lung cancer who received the KRAS G12C inhibitor adagrasib.

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

June 09, 2021

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.

Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCC

May 20, 2020

Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.